Search Results

Business

IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024

IceCure Medical Ltd. today reported financial results as of and for the three months ended March 31, 2024.

May 28, 2024

·

17 min read

IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024

IceCure Medical Ltd. today announced the Company’s management, will participate in the Northland Capital Markets Virtual Growth Conference on Tuesday, June 25, 2024.

June 18, 2024

·

5 min read

U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes

IceCure Medical Ltd. (NASDAQ: ICCM) (“IceCure”, “IceCure Medical” or the “Company”) today announced it has received marketing authorization from the United States Food and Drug Administration (the “FDA”) for its next-generation single probe cryoablation system, the XSense™ Cryoablation System with CryoProbes.

July 1, 2024

·

4 min read

Business

IceCure Medical Reports Full Year 2023 Financial Results

IceCure Medical Ltd. today reported sales as of and for the twelve months ended December 31, 2023.

April 3, 2024

·

17 min read

Business

IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024

IceCure Medical Ltd. announced today that it will issue a press release containing its financial and operational results as of and for the three months ended March 31, 2024 before the Nasdaq Stock Market opens on Tuesday, May 28, 2024.

May 21, 2024

·

3 min read

Business

IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024 - May 21, 2024

IceCure Medical Ltd. announced today that it will issue a press release containing its financial and operational results as of and for the three months ended March 31, 2024 before the Nasdaq Stock Market opens on Tuesday, May 28, 2024.

May 21, 2024

·

3 min read

Business

IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024

IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”) today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2023 before the Nasdaq Stock Market opens on Wednesday, April 3, 2024.

March 27, 2024

·

4 min read

Positive Data from IceCure’s Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function

IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”) today announced that data from an interim analysis of its ICESECRET kidney cancer trial were presented at the 3rd Annual Israeli Conference on Interventional Radiology in Tel Aviv, Israel on June 10, 2024.

June 12, 2024

·

5 min read

FDA to Convene Advisory Panel for Review of IceCure’s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan

IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”) today announced the U.S. Food and Drug Administration (“FDA”) will convene a Medical Device Advisory Committee for a panel meeting (the “Advisory Panel”) to obtain independent expert advice on scientific, technical, and policy matters related to ProSense® to help the FDA make a sound decision.

June 4, 2024

·

6 min read

IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners’ Virtual Healthcare Company Showcase

IceCure Medical Ltd. today announced the Company’s CEO, Eyal Shamir, will present via a fireside chat at the A.G.P / Alliance Global Partners’ Virtual Healthcare Company Showcase on Tuesday, May 21, 2024, at 8:20am EDT.

May 20, 2024

·

2 min read